Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 4 news stories from 4 outlets.

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly…

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent…

SAN FRANCISCO, September 28, 2025 A new clinical trial finds that people with a limited number of metastases from recurrent…

TOPLINE: Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.